Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday - Abbott Laboratories (NYSE:ABT)
Analysts updated price targets for several companies. Argus raised Accenture's target to $260, Susquehanna cut CSX's to $55, and Rothschild upgraded Abbott Labs to Buy with a $127 target. Other notable changes include Synaptics, Nike, AtriCure, McCormick, Foghorn, Marathon, and Shattuck Labs.
How this was made
The 30-second read
Why it matters
Provides a snapshot of analyst sentiment shifts that may influence short-term price movements for the listed tickers.
Market read
Analyst revisions can cause modest price adjustments; the most notable move is Abbott's upgrade.
What to watch
Underlying earnings results and broader market momentum are not discussed, which could mitigate the impact of these target changes.
Background
The article aggregates recent analyst price target changes and rating updates for a set of U.S.-listed companies, including Abbott Laboratories.
Ticker impact
Rothschild & Co raised Abbott Laboratories price target to $127 and upgraded to Buy.
likely upward pressure as market prices in the higher target
Target raise of $8 (~8%) and upgrade to Buy suggest improved outlook.
Argus Research raised Accenture price target to $260 from $220.
likely upward pressure from higher target
Target increase of ~18% signals bullish view.
Susquehanna cut CSX price target to $55 from $59.
potential downward pressure as target is lowered
Target reduction of ~7% reflects weaker outlook.
Rosenblatt raised Synaptics price target to $123 from $115.
likely upward pressure from higher target
Target increase of ~7% indicates improved expectations.
Baird cut Nike price target to $36 from $44.
potential downward pressure as target is cut
Target reduction of ~18% signals weaker outlook.
Freedom Capital Markets raised AtriCure price target to $57 from $43 but downgraded rating to Hold.
limited impact; target rise may offset downgrade
Target up ~33% but rating downgrade tempers enthusiasm.
Stifel cut McCormick price target to $48 from $55.
potential downward pressure from lower target
Target cut of ~13% reflects weaker view.
HC Wainwright lowered Foghorn Therapeutics price target to $5 from $13.
strong downward pressure as target drops ~62%
Large target reduction indicates serious concerns.
Market effects
Analyst target revisions may slightly shift sentiment in healthcare, tech, industrials and consumer sectors.
U.S. equity markets may see modest adjustments in the affected stocks but no broad market move.
Limited to U.S. listed companies; no global macro impact.
Counterpoint
Target cuts could be overreactions; price may rebound if earnings beat expectations.
Key entities
- CompanyAbbott Laboratories
Subject of a price target raise and upgrade to Buy.
- CompanyAccenture Plc
Target raised to $260.
- CompanyCSX Corp
Target cut to $55.
